Home › Funds › ANTIPODES PARTNERS Ltd › ALNY
ANTIPODES PARTNERS Ltd position in ALNY
ALNYLAM PHARMACEUTICALS INC · Health Care
ANTIPODES PARTNERS Ltd reported holding 175,869 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$43.4M, representing 0.80% of its reported portfolio and ranking #45 among its reported holdings. ANTIPODES PARTNERS Ltd has disclosed ALNY holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How ANTIPODES PARTNERS Ltd's ALNY position evolved
ANTIPODES PARTNERS Ltd first disclosed a stake in ALNY in Q3 2023 at 111,834 shares (US$19.5M). The position peaked in Q2 2024 at 238,749 shares, worth US$59.4M. Across 13 filings, ANTIPODES PARTNERS Ltd increased the stake 8 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 175,869 shares valued at US$43.4M — an increase of 12,336 shares quarter over quarter.. Notable position changes include a 69% increase in Q4 2023 (shares fell 22% over the following quarter), a 74% trim in Q3 2025 (shares fell 13% over the following quarter), a 203% increase in Q1 2026 (shares fell 8% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 111.83K | $19.46M | New |
| Q4 2023 | 189.14K | $36.20M | Add |
| Q1 2024 | 205.58K | $30.72M | Add |
| Q2 2024 | 238.75K | $59.43M | Add |
| Q3 2024 | 139.38K | $38.34M | Reduce |
| Q4 2024 | 133.76K | $31.48M | Reduce |
| Q1 2025 | 159.55K | $43.09M | Add |
| Q2 2025 | 122.80K | $40.05M | Reduce |
| Q3 2025 | 31.96K | $14.57M | Reduce |
| Q4 2025 | 47.89K | $19.04M | Add |
| Q1 2026 | 145.31K | $48.08M | Add |
| Q2 2026 | 163.53K | $49.23M | Add |
| Q3 2026 | 175.87K | $43.39M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALNY and 13F data
ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 30 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$1.36B), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALNY
- T. Rowe Price Investment Management, Inc. 5.64M sh · $1.70B · Q2 2026
- Baillie Gifford & Co 5.49M sh · $1.36B · Q3 2026
- Orbis Allan Gray Ltd 1.99M sh · $598.27M · Q2 2026
- Two Sigma Investments 1.88M sh · $564.71M · Q2 2026
- TWO SIGMA ADVISERS, LP 1.13M sh · $450.36M · Q4 2025
- Deep Track Capital, LP 825.00K sh · $248.35M · Q2 2026
More on ANTIPODES PARTNERS Ltd
FAQ
How long has ANTIPODES PARTNERS Ltd held ALNY?
ANTIPODES PARTNERS Ltd has disclosed ALNY holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is ANTIPODES PARTNERS Ltd's current position in ALNY?
As of Q3 2026, ANTIPODES PARTNERS Ltd holds 175.87K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $43.39M, representing 0.80% of its reported portfolio and ranking #45.
Has ANTIPODES PARTNERS Ltd been buying or selling ALNY?
In the latest 13F filing (Q3 2026), ANTIPODES PARTNERS Ltd increased its position in ALNY. The position peaked in Q2 2024 at 238.75K shares.
Which other funds hold ALNY?
Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.